HUMACYTE
Humacyte develops products for vascular disease and replacement of anatomical conduits. It offers human tissue-based products for regenerative medicine and vascular surgery applications; off-the-shelf extracellular matrix tissue products, which are formed in vitro from banked vascular smooth muscle cells and then decellularized to eliminate the risk of rejection; and vascular grafts.
HUMACYTE
Industry:
Biotechnology Medical Medical Device
Founded:
2004-01-01
Address:
Morrisville, North Carolina, United States
Country:
United States
Website Url:
http://www.humacyte.com
Total Employee:
101+
Status:
Active
Contact:
9193139634
Email Addresses:
[email protected]
Total Funding:
692.86 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Font API Google Analytics Apple Mobile Web Clips Icon Google Tag Manager WordPress Content Delivery Network Google Universal Analytics Global Site Tag
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Fresenius Medical Care
Fresenius Medical Care investment in Post-IPO Equity - Humacyte
OrbiMed
OrbiMed investment in Post-IPO Equity - Humacyte
Alexandria Venture Investments
Alexandria Venture Investments investment in Post-IPO Equity - Humacyte
Morgan Creek Capital Management
Morgan Creek Capital Management investment in Post-IPO Equity - Humacyte
UBS O'Connor
UBS O'Connor investment in Post-IPO Equity - Humacyte
Monashee Investment Management
Monashee Investment Management investment in Post-IPO Equity - Humacyte
Silicon Valley Bank
Silicon Valley Bank investment in Debt Financing - Humacyte
Fresenius Medical Care
Fresenius Medical Care investment in Corporate Round - Humacyte
California Institute for Regenerative Medicine
California Institute for Regenerative Medicine investment in Grant - Humacyte
California Institute for Regenerative Medicine
California Institute for Regenerative Medicine investment in Venture Round - Humacyte
Key Employee Changes
Official Site Inspections
http://www.humacyte.com Semrush global rank: 4.77 M Semrush visits lastest month: 1.94 K
- Host name: ec2-67-202-46-212.compute-1.amazonaws.com
- IP address: 67.202.46.212
- Location: Ashburn United States
- Latitude: 39.0481
- Longitude: -77.4728
- Metro Code: 511
- Timezone: America/New_York
- Postal: 20149
More informations about "Humacyte"
Leadership - Humacyte Global, Inc.
Jul 23, 2024 Dr. Niklason is the founder of Humacyte and has served as its President and CEO since 2020. She served Humacyte as a senior scientist from 2004 through 2020. ... Mr. …See details»
Humacyte - Crunchbase Company Profile & Funding
Humacyte develops products for vascular disease and replacement of anatomical conduits. It offers human tissue-based products for regenerative medicine and vascular surgery …See details»
Our Story - Humacyte Global, Inc.
Jul 23, 2024 Our commitment to disruptive, meaningful innovation goes beyond mere advancement. It’s a dedication to setting new standards that challenge the status quo and …See details»
Humacyte - The Org
Humacyte, Inc., is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients …See details»
Humacyte, Inc. Announces Proposed Public Offering of Common …
2 hours ago DURHAM, N.C., March 25, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally …See details»
Org Chart Humacyte - The Official Board
Organizational Chart of Humacyte. Humacyte www.humacyte.com. has 21 executives +1 919 313 9633; Add an executive. Humacyte (HUMA) News . Anything missing? We search for you. …See details»
Investor Relations - Humacyte, Inc.
Humacyte, Inc. (Nasdaq: HUMA) is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues, advanced tissue constructs, and organ …See details»
Humacyte, Inc. Announces Proposed Public Offering of Common
2 hours ago Humacyte Investor Contact: Joyce Allaire LifeSci Advisors LLC +1-617-435-6602 [email protected] [email protected]. Humacyte Media Contact: Rich …See details»
Humacyte - Funding, Financials, Valuation & Investors - Crunchbase
Humacyte is registered under the ticker NASDAQ:HUMA . Humacyte is funded by 15 investors. Fresenius Medical Care and OrbiMed are the most recent investors. Humacyte has a post …See details»
Annual Reports - Humacyte, Inc.
Mar 29, 2022 The Investor Relations website contains information about Humacyte, Inc.'s business for stockholders, potential investors, and financial analysts.See details»
Humacyte, Inc. (HUMAW) Company Profile & Overview
Mar 10, 2025 Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions …See details»
Humacyte - Contacts, Employees, Board Members, Advisors
Humacyte develops products for vascular diseases and replacement of anatomical conduits. New. Resources. Advanced Search ... Experience the new Crunchbase, powered by AI . Experience …See details»
Humacyte Company Profile - Office Locations, Competitors ... - Craft
Oct 29, 2024 Humacyte is a regenerative medical technology company focused on the development of human acellular matrix products for vascular and non-vascular applications. It …See details»
Humacyte, Inc. (HUMA) Company Profile & Facts - Yahoo Finance
See the company profile for Humacyte, Inc. (HUMA) including business summary, industry/sector information, number of employees, business summary, corporate governance, key executives …See details»
Humacyte - Overview, News & Similar companies | ZoomInfo.com
Humacyte to Present Second Quarter Financial Results and Provide Corporate Update on August 13, 2024 DURHAM, N.C., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: …See details»
Bioengineering Process - Humacyte Global, Inc.
Our first-in-class bioengineering technology and manufacturing process aims to transform human cells into universally implantable, regenerative tissues and advanced organ systems, for use in …See details»
Humacyte, Inc. - AnnualReports.com
Humacyte, Inc. (Nasdaq: HUMA) is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the …See details»
A Deep Dive Into Humacyte Inc: Pioneering Bioengineered Human …
Dec 23, 2024 Humacyte Inc was founded in 2004 by Dr. Laura Niklason, a Yale professor and one of the world’s leading experts in vascular and tissue engineering. Her groundbreaking …See details»
Humacyte down 13% amid reports that FDA approved device …
3 hours ago A former U.S. FDA employee said he and other agency reviewers were pressured to approve Humacyte's (NASDAQ:HUMA) Symvess, an artificial blood vessel, despite safety …See details»
Support & Resources - Humacyte Global, Inc.
Humacyte® is dedicated to delivering exceptional value to clinicians across various therapeutic areas and healthcare settings, all with a focus on prioritizing patient care. Our extensive …See details»